01-03-2022
Pavel Kapysh / Shutterstock.com
Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
COVID-19, Arbutus, Genevant, sue, Moderna, dispute, vaccine, LNPs
Moderna secures COVID-19 vaccine delivery win before appeals court
12-04-2023
US govt wades into Moderna COVID row
15-02-2023
Moderna hits Pfizer and BioNTech with COVID-19 vaccine patent suit
30-08-2022
Arbutus, Genevant reject Moderna’s vaccine patent defence
07-06-2022
Generic Emcure stole COVID-19 vaccine trade secrets, lawsuit claims
22-03-2022
Genevant signs $600m liver fibrosis deal with Takeda
18-03-2021
